Infective endocarditis resident survival guide: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) No edit summary |
||
Line 92: | Line 92: | ||
'''Abdomen'''<BR> | '''Abdomen'''<BR> | ||
❑ [[Reduced bowel sounds]] (sign of [[ | ❑ [[Reduced bowel sounds]] (sign of mesenteric [[embolism|embolization]] or [[ileus]])<BR> | ||
❑ [[Abdominal pain]]<BR> | ❑ [[Abdominal pain]]<BR> | ||
:❑ [[Flank pain]] (sign of [[embolus to the kidney]])<BR> | :❑ [[Flank pain]] (sign of [[embolus to the kidney]])<BR> | ||
Line 102: | Line 102: | ||
❑ [[Janeway lesion]]s (painless hemorrhagic cutaneous lesions on the palms and soles)<BR> | ❑ [[Janeway lesion]]s (painless hemorrhagic cutaneous lesions on the palms and soles)<BR> | ||
❑ [[Gangrene]] of fingers<BR> | ❑ [[Gangrene]] of fingers<BR> | ||
❑ [[Splinter | ❑ [[Splinter hemorrhage]]s<BR> | ||
❑ [[Osler's node]]s (painful subcutaneous lesions in the distal fingers)<BR> | ❑ [[Osler's node]]s (painful subcutaneous lesions in the distal fingers)<BR> | ||
Line 125: | Line 125: | ||
:❑ Prosthetic valve with persistent fever without bacteremia ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]]) | :❑ Prosthetic valve with persistent fever without bacteremia ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]]) | ||
:❑ Prosthetic valve with a new murmur ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]]) | :❑ Prosthetic valve with a new murmur ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]]) | ||
:❑ Nosocomial Staphylococcus aureus bacteremia with known extra-cardiac port of entry ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence B]]) | :❑ Nosocomial Staphylococcus aureus [[bacteremia]] with known extra-cardiac port of entry ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence B]]) | ||
</div>}} | </div>}} | ||
{{familytree | |!| | | | | |}} | {{familytree | |!| | | | | |}} | ||
Line 147: | Line 147: | ||
❑ Begin [[Endocarditis antimicrobial treatment|antibiotic treatment]]<br> | ❑ Begin [[Endocarditis antimicrobial treatment|antibiotic treatment]]<br> | ||
❑ Order blood cultures very 24-48 hours until no [[bacteremia]] can be detected<br> | ❑ Order blood cultures very 24-48 hours until no [[bacteremia]] can be detected<br> | ||
❑ Temporarily discontinue anticoagulation if one of the following is present | ❑ Temporarily discontinue [[anticoagulation]] if one of the following is present | ||
:❑ Signs and symptoms of CNS involvement consistent with embolism or stroke ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]]) | :❑ Signs and symptoms of [[CNS]] involvement consistent with embolism or [[stroke]] ([[ACC AHA guidelines classification scheme|Class IIa, level of evidence B]]) | ||
:❑ Vitamin K antagonist administration ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence B]]) | :❑ Vitamin K antagonist administration ([[ACC AHA guidelines classification scheme|Class IIb, level of evidence B]]) | ||
❑ Schedule early surgery during hospitalization before completion of the antibiotics course if one of the following is present | ❑ Schedule early surgery during hospitalization before completion of the antibiotics course if one of the following is present | ||
Line 187: | Line 187: | ||
:❑ Atrioventricular heart block | :❑ Atrioventricular heart block | ||
❑ High risk of complications | ❑ High risk of complications | ||
:❑ Large vegetations on echocardiogram | :❑ Large vegetations on [[echocardiogram]] | ||
:❑ Staphylococcus, enterecoccal, or fungal infections | :❑ Staphylococcus, enterecoccal, or fungal infections | ||
</div>}} | </div>}} | ||
Line 269: | Line 269: | ||
❑ [[Cardiac transplant]] recipients with valves regurgitation due to structurally abnormal valve<BR> | ❑ [[Cardiac transplant]] recipients with valves regurgitation due to structurally abnormal valve<BR> | ||
❑ [[Congenital heart diseases]]<BR> | ❑ [[Congenital heart diseases]]<BR> | ||
:❑ Unrepaired cyanotic congenital heart diseases | :❑ Unrepaired cyanotic [[congenital heart diseases]] | ||
:❑ Completely repaired defect with prosthetic material or device | :❑ Completely repaired defect with prosthetic material or device | ||
:❑ Repaired with residual defects</div>}} | :❑ Repaired with residual defects</div>}} | ||
Line 335: | Line 335: | ||
** Placement or removal of prosthodontic or orthodontic appliances | ** Placement or removal of prosthodontic or orthodontic appliances | ||
** Adjustment of orthodontic appliances | ** Adjustment of orthodontic appliances | ||
** Bleeding following trauma to the oral mucosa or lips<ref name="pmid18820172">{{cite journal |author=Bonow RO, Carabello BA, Chatterjee K, ''et al.'' |title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=Circulation |volume=118 |issue=15 |pages=e523–661 |year=2008 |month=October |pmid=18820172 |doi=10.1161/CIRCULATIONAHA.108.190748 |url=}}</ref> | ** [[Bleeding]] following trauma to the oral mucosa or lips<ref name="pmid18820172">{{cite journal |author=Bonow RO, Carabello BA, Chatterjee K, ''et al.'' |title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons |journal=Circulation |volume=118 |issue=15 |pages=e523–661 |year=2008 |month=October |pmid=18820172 |doi=10.1161/CIRCULATIONAHA.108.190748 |url=}}</ref> | ||
* Do not administer infective endocarditis prophylaxis for procedures involving the [[respiratory tract]] unless they involve incision of the respiratory tract mucosa.<ref name="pmid18820172">{{cite journal| author=Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD et al.| title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | journal=Circulation | year= 2008 | volume= 118 | issue= 15 | pages= e523-661 | pmid=18820172 | doi=10.1161/CIRCULATIONAHA.108.190748 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18820172 }} </ref> | * Do not administer infective endocarditis prophylaxis for procedures involving the [[respiratory tract]] unless they involve incision of the respiratory tract [[mucosa]].<ref name="pmid18820172">{{cite journal| author=Bonow RO, Carabello BA, Chatterjee K, de Leon AC, Faxon DP, Freed MD et al.| title=2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. | journal=Circulation | year= 2008 | volume= 118 | issue= 15 | pages= e523-661 | pmid=18820172 | doi=10.1161/CIRCULATIONAHA.108.190748 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18820172 }} </ref> | ||
* Do not administer [[cephalosporins]] in subjects with a previous history of [[anaphylaxis]], [[angioedema]], or [[urticaria]] following [[penicillin]] or [[ampicillin]] use. | * Do not administer [[cephalosporins]] in subjects with a previous history of [[anaphylaxis]], [[angioedema]], or [[urticaria]] following [[penicillin]] or [[ampicillin]] use. |
Revision as of 23:32, 8 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farman Khan, MD, MRCP [2]; Mohamed Moubarak, M.D. [3]; Rim Halaby, M.D. [4]
Synonyms and keywords: IE
Definition
Infective endocarditis is the infection of the endothelium of the heart including but not limited to the valves. While acute bacterial endocarditis is caused by an infection with a virulent organism such as staphylococcus aureus, group A or other beta-hemolytic streptococci, subacute bacterial endocarditis is an indolent infection with less virulent organisms like streptococcus viridans.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated. Endocarditis can be a life-threatening condition if it is left untreated, and it must be treated as such irrespective of the causes.
Common Causes
Management
Shown below is an algorithm depicting the management of infective endocarditis.[1][2]
Characterize the symptoms: ❑ Onset of the symptoms
❑ Fever | |||||||||||||||||||||||
Identify existing risk factors: ❑ History of rheumatic heart disease | |||||||||||||||||||||||
Examine the patient: Vital signs
Skin ❑ Petechiae Dental examination Eyes ❑ Conjunctival hemorrhage Heart Lungs ❑ Rales as a sign of heart failure Abdomen ❑ Reduced bowel sounds (sign of mesenteric embolization or ileus)
Extremities ❑ Janeway lesions (painless hemorrhagic cutaneous lesions on the palms and soles) Neurologic ❑ Full neurological exam
| |||||||||||||||||||||||
If the patient has any of the following proceed with tests: ❑ Unexplained fever for more than 48 hours and high risk for infective endocarditis, OR | |||||||||||||||||||||||
Order tests: ❑ Blood culture (at least two sets)
| |||||||||||||||||||||||
Evaluate the Modified Duke Criteria for infective endocarditis:[3]
| |||||||||||||||||||||||
Once the diagnosis of infective endocarditis is confirmed, initiate the treatment:
❑ Begin antibiotic treatment
❑ Schedule early surgery during hospitalization before completion of the antibiotics course if one of the following is present
❑ Remove the pacemaker of the defibrillator system if one of the following is present
| |||||||||||||||||||||||
Manage the patient with a multidisciplinary team: ❑ Consult an infectious disease specialist ❑ Consult a cardiologist ❑ Consult a cardiac surgeon | |||||||||||||||||||||||
Follow up the patient: ❑ Repeat TTE
| |||||||||||||||||||||||
Reevaluate the patient with TTE and/or TEE if one of the following is present: ❑ Change in clinical signs and symptoms
❑ High risk of complications
| |||||||||||||||||||||||
TEE: Transesophageal echocardiocardiography; TTE: Transthoracic echocardiocardiography
Antibiotic Regimens
A complete list of pathogen specific antibiotics regimens with appropriate dosages and duration of treatment is available here.
Modified Duke Criteria
Shown below is a table summarizing the major and minor Modified Duke Criteria.[3]
|
Prophylaxis
Shown below is an algorithm depicting the general prophylactic approaches of infective endocarditis.[4][1]
Identify high risk patients: (Class IIa, Level of evidence B)
❑ Prosthetic valves patients
| |||||||||
Identify high risk procedures:
❑ Respiratory tract procedures involving incision of the respiratory tract mucosa ❑ Gastrointestinal (GI) and genitourinary (GU) procedures only if GI or GU tract infection is present | |||||||||
❑ Administer prophylaxis
| |||||||||
Antibiotic Prophylaxis
Shown below is a table depicting the prophylaxis antibiotic regimes for infective endocarditis.[1]
|
Do's
- Elicit a full medical history to identify the minor Duke criteria for the diagnosis.
- Consider alternative diagnoses for bacteremia and fever by searching for focus of infections.
- Initiate antibiotic therapy after withdrawing blood for culture (Class I, level of evidence B).[1]
- If the blood cultures are negative in a patient suspected to have infective endocarditis, suspect HACEK infection and ask the laboratory to retain the blood cultures for more than two weeks.[2]
- If HACEK bacteremia is detected without any focus of infection, suspect the presence of infective endocarditis even in the absence of the typical signs and symptoms.[2]
- Do a TEE intraoperatively among patients scheduled for valve surgery for infective endocarditis (Class I, level of evidence B).[1]
- Consider ordering a cardiac CT scan when echocardiography does not provide clear details about the cardiac anatomy in the context of suspected paravalvular infections (Class IIa, level of evidence B).[1]
Dont's
- Don't administer prophylaxis for infective endocarditis in patients with valvular heart disease who are at risk infective endocarditis for procedures such as TEE, cystoscopy, esophagogastroduodenoscopy or colonoscopy without any evidence of active infection (Class III; level of evidence B).[1]
- Do not administer infective endocarditis prophylaxis for the following dental procedures:
- Do not administer infective endocarditis prophylaxis for procedures involving the respiratory tract unless they involve incision of the respiratory tract mucosa.[5]
- Do not administer cephalosporins in subjects with a previous history of anaphylaxis, angioedema, or urticaria following penicillin or ampicillin use.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary". Retrieved 4 March 2014.
- ↑ 2.0 2.1 2.2 Baddour, LM.; Wilson, WR.; Bayer, AS.; Fowler, VG.; Bolger, AF.; Levison, ME.; Ferrieri, P.; Gerber, MA.; Tani, LY. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145. Unknown parameter
|month=
ignored (help) - ↑ 3.0 3.1 Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T; et al. (2000). "Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis". Clin Infect Dis. 30 (4): 633–8. doi:10.1086/313753. PMID 10770721.
- ↑ Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M; et al. (2007). "Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group". Circulation. 116 (15): 1736–54. doi:10.1161/CIRCULATIONAHA.106.183095. PMID 17446442.
- ↑ 5.0 5.1 Bonow RO, Carabello BA, Chatterjee K; et al. (2008). "2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Circulation. 118 (15): e523–661. doi:10.1161/CIRCULATIONAHA.108.190748. PMID 18820172. Unknown parameter
|month=
ignored (help)